Skip to main content
OpenTrials
Completed

NCT Number: NCT01969370

NCGENES: North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing

This study is part of a larger consortium project investigating the validity and best use of next-generation sequencing (in particular, whole exome sequencing, or WES) in clinical care. This sub-project is investigating benefits and harms of providing WES diagnostic and different types of incidental findings to adult patients and parents of pediatric patients who undergo WES because they have symptoms suggesting genetic disease.

Completed

Looking for future studies?

Notify Me

Key information

About this study

This study is part of a larger consortium project investigating the validity and best use of next-generation sequencing (in particular, whole exome sequencing, or WES) in clinical care. Participants are patients who were either seen in the University of North Carolina Cancer and Adult Genetics Clinic or referred to the study by their physician. They will be approached by their physician or a genetic counselor for recruitment. Once enrolled, a clinical geneticist or genetic counselor will obtain consent and collect blood samples to be analyzed using WES. Results may include information related to a diagnosis and incidental information. Medically actionable incidental findings will be CLIA (Clinical Laboratory Improvement Amendments)-certified and returned to participants in a routine genetic counseling session, along with diagnostic findings. Eligible adult participants will be randomized to have the opportunity to choose to get certain types of non-medically actionable incidental findings, as well. Their decisions will be investigated, as will psychosocial and behavioral responses to sequencing and receiving sequencing information. This is a longitudinal, mixed methods study (i.e., multiple assessments pre- and post-return of results, with both quantitative and qualitative methods used to gather data). Because only the quantitative component of the study uses randomization, only measures and procedures associated with that component are described here.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

  • To receive whole exome sequencing in the study, adult or child patients must have a significant chance of having a genetic disorder, as determined by experts on the study team using criteria that depend on the genetic disorder in question. Representative criteria are listed below and will be considered together to determine whether patterns indicate a likely genetic etiology.

Cancer

  • Age of diagnosis
  • Presence of bilateral (or multiple) cancers
  • Diagnosis of a rare type of cancer
  • Details of the family history

Cardiovascular Conditions

  • Certain clinical findings, such as prolonged QT interval on electrocardiogram.
  • Presence of hypertrophic cardiomyopathy or aortic aneurysm
  • Age of diagnosis
  • Presence of family history

Pediatric neurodevelopmental disorders

  • Specific brain structural brain abnormalities
  • Presence of certain seizure types
  • Dysmorphic features

Treatment and study plan

Experimental

Behavioral

Option to request non-medically actionable incidental information (after receiving education about them)

Primary outcomes

  1. Extent of test-specific distress 2 weeks after return of results

    Time frame: 2 weeks after return of diagnostic results; for adult patient participants who are eligible and who request them, 2 weeks after return of non-medically actionable incidental results

    Measured with an adapted version of the multidimensional impact of testing scale (MICRA)

Secondary outcomes

  1. Change in test-specific distress at 3 and 6 months after return of results

    Time frame: Adult patient participants: change from 2 weeks after return of diagnostic results to 3 months and 6 months after return of diagnostic results

    Measure is an adapted version of the multidimensional impact of testing scale MICRA)

  2. Extent of communication of test results with other people

    Time frame: 2 weeks after return of diagnostic results

    Motivations of communications will also be assessed and examined for descriptive analyses.

  3. Extent of information seeking

    Time frame: 2 weeks after consent (T1) and change from T1 to 2 weeks after return of diagnostic results

    Participants will answer questions about the extent to which they sought information about whole exome sequencing and results it produces. Questions also ask about sources of that information (e.g., the Internet, doctors) to provide descriptive data about how participants get information.

  4. Extent of Decision Regret 2 weeks after consent

    Time frame: All participants: 2 wks after consent (T1)

  5. Extent of Decision Regret 2 weeks after return of results

    Time frame: All participants: 2 wks after return of diagnostic (dx) results and, for eligible adults who request them, return of incidental results

    Also administered 2 wks after return of non-medically actionable incidental results for eligible adult patient participants who request them.

  6. Change in decision regret

    Time frame: For all participants: Change from post-consent to post-return of results; Additional for adults: change at 3 and 6 months after return of dx results

  7. Extent of Healthcare Utilization 2 weeks after consent

    Time frame: All participants: 2 wks after consent (T1)

  8. Extent of Healthcare Utilization 2 weeks after return of results

    Time frame: All participants: 22 wks after return of diagnostic (dx) results

  9. Change in Healthcare Utilization

    Time frame: All participants: Change in utilization from post-consent to post-return of results; Additional for adult patients: Change at 3 and 6 months after return of dx results

  10. Enactment of health-related lifestyle behaviors 2 weeks after consent

    Time frame: Adult participants: 2 wks after consent (T1)

    Behaviors include those related to diet, physical activity, smoking, drinking, and substance use.

  11. Enactment of health-related lifestyle behaviors 2 weeks after return of results

    Time frame: Adult participants: 2 wks after return of diagnostic (dx) results

    Behaviors include those related to diet, physical activity, smoking, drinking, and substance use.

  12. Change in enactment of health-related lifestyle behaviors

    Time frame: Adult participants: Change in behaviors from 2 wks after consent (T1) to 2 wks, 3 months, and 6 months after return of dx results

    Behaviors include those related to diet, physical activity, smoking, drinking, and substance use.

  13. Extent of psychological distress 2 weeks after consent

    Time frame: All participants: 2 wks after consent

    Symptoms of depression and anxiety measured with the Hospital Anxiety and Depression Scale

  14. Extent of psychological distress 2 weeks after return of results

    Time frame: All participants: 2 wks after return of diagnostic (dx) results

    Symptoms of depression and anxiety measured with the Hospital Anxiety and Depression Scale

  15. Change in extent of psychological distress

    Time frame: All participants: Change from 2 wks after consent (T1) to 2 wks after return of diagnostic (dx) results; Additional for adult patients: Change at 3 and 6 months after return of dx results

    Symptoms of depression and anxiety measured with the Hospital Anxiety and Depression Scale

  16. Extent of health-related Quality of Life 2 weeks after consent

    Time frame: All participants: 2 wks after consent (T1)

    Measured with the Medical Outcomes Study Short Form-12

  17. Extent of health-related Quality of Life 2 weeks after return of results

    Time frame: All participants: 2 wks after return of diagnostic results

    Measured with the Medical Outcomes Study Short Form-12

  18. Change in extent of health-related Quality of Life

    Time frame: All participants: Change from 2 wks after consent to 2 weeks after return of diagnostic results

    Measured with the Medical Outcomes Study Short Form-12

Sponsors and collaborators

Lead sponsor

University of North Carolina, Chapel Hill

Other

Collaborators

  • National Human Genome Research Institute (NHGRI)
  • UNC Lineberger Comprehensive Cancer Center

Registry information

Acronym: NCGENES

Important dates

Study start
2012
Primary completion
2017
Study completion
2017
First posted
Oct 25, 2013
Registry last updated
May 3, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.